Autoantibodies occur in many different nervous system disorders, and are increasingly being found in disorders not traditionally associated with the immune system. Determining if the autoantibodies play a functional or pathogenic role is critical in selecting the most appropriate treatment options.
Browsing: Immune disorders and inflammation
Milan Fiala and Matteo Pellegrini review current research that indicates a role for omega-3 fatty acids in slowing the progression of mild cognitive impairment.
In this edition of NCTalks, we speak to Robyn Klein as part of our Spotlight on neuroimmunology – Robyn discusses her research, how inflammatory processes contribute to neurologic disease, and whether immunology and inflammation could be the basis of an eventual preventative treatment for neurodegenerative disease.
Dr Coffman is currently studying the mechanisms by which chronic early-life stress increases adult disease risk, using zebrafish as a model organism to ask how such stress affects immune system development and regulation.
Available to view on demand
Epidemiological studies have shown that chronic stress experienced very early in life—even prenatally—increases the risk of developing inflammatory disease in adulthood, including mental health disorders such as anxiety and depression.
Karmakar & Reilly review what is known about the role of NF1 mutation in immune cell function & the role of immune cells in promoting tumorigenesis in NF1.
In this interview, Dr Akassoglou discusses her pioneering research, as well as the key challenges in this exciting area of neuroscience and her hopes for the field.
Dr Paul Gallagher (Institute of Neurological Sciences, Glasgow, UK) provides an overview of these two recent papers by Jokubaitis and colleagues  and Cree and colleagues, which both assessed factors predictive of long-term disability outcomes in people with multiple sclerosis (MS).
Researchers have identified a dysfunctional cell receptor in the immune system that could be part of the cause of chronic fatigue syndrome.
In the quest to cross the BBB, researchers have developed immunoliposomes targeted to BBB receptors and α-synuclein that could potentially enable the transport of drugs to reach one of the drug targets in Parkinson’s disease.